![Xiayang Qiu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Xiayang Qiu
Sociétés | Poste | Début | Fin |
---|---|---|---|
Regor Therapeutics Group
![]() Regor Therapeutics Group Miscellaneous Commercial ServicesCommercial Services Regor Therapeutics Group is a biotech company founded in 2018 by a team of scientists with expertise in drug discovery and development. The company is based in Boston, MA and has subsidiaries in China. Regor Therapeutics Group utilizes its industry-leading core strength in Rcard™ to accelerate the discovery of innovative therapeutic agents. The company has completed 8 PCCs in-house, with 5 INDs filed, and has a pipeline of leading assets in metabolism, oncology, and auto-immunity. The company's two leading assets are RGT-075, an orally bioavailable small molecule GLP1R full agonist with potential for obesity and beyond, and RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/HER2- breast cancer patients. The company was founded in 2018, and the CEO is Xiayang Qiu. | Directeur Général | - | - |
QILU Regor Therapeutics, Inc. | Directeur Général | 01/01/2018 | - |
Fondateur | 01/01/2018 | - |
Historique de carrière de Xiayang Qiu
Statistiques
Internationale
Etats-Unis | 2 |
Chine | 2 |
Opérationnelle
Chief Executive Officer | 2 |
Founder | 1 |
Sectorielle
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Regor Therapeutics Group
![]() Regor Therapeutics Group Miscellaneous Commercial ServicesCommercial Services Regor Therapeutics Group is a biotech company founded in 2018 by a team of scientists with expertise in drug discovery and development. The company is based in Boston, MA and has subsidiaries in China. Regor Therapeutics Group utilizes its industry-leading core strength in Rcard™ to accelerate the discovery of innovative therapeutic agents. The company has completed 8 PCCs in-house, with 5 INDs filed, and has a pipeline of leading assets in metabolism, oncology, and auto-immunity. The company's two leading assets are RGT-075, an orally bioavailable small molecule GLP1R full agonist with potential for obesity and beyond, and RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/HER2- breast cancer patients. The company was founded in 2018, and the CEO is Xiayang Qiu. | Commercial Services |
QILU Regor Therapeutics, Inc. |
- Bourse
- Insiders
- Xiayang Qiu
- Expérience